

CORRECTION


Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study

María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban

The second affiliation for the sixth author is not indicated. Martín Prieto is also affiliated with: CIBEREHD, Instituto Carlos III, Madrid, Spain.

Reference

1. Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. (2017) Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS ONE 12(9): e0184550. <https://doi.org/10.1371/journal.pone.0184550> PMID: 28898281



OPEN ACCESS

Citation: Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. (2018) Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS ONE 13(6): e0199926. <https://doi.org/10.1371/journal.pone.0199926>

Published: June 25, 2018

Copyright: © 2018 Buti et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.